From November 6, 2023 to December 31, 2023, the company has repurchased 4,057,100 shares, representing 0.28% for CNY 61.58 million. With this, the company has completed the repurchase of 4,057,100 shares, representing 0.28% for CNY 61.58 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.34 CNY | -0.63% | -0.74% | +18.20% |
13/05 | Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution | MT |
02/05 | Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.20% | 351.2Cr | |
+29.98% | 68TCr | |
+30.88% | 59TCr | |
-3.52% | 36TCr | |
+18.59% | 33TCr | |
+4.07% | 28TCr | |
+16.70% | 24TCr | |
+9.77% | 21TCr | |
-8.47% | 20TCr | |
+7.09% | 17TCr |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.